These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
561 related articles for article (PubMed ID: 34661893)
41. The role of cell death in SARS-CoV-2 infection. Yuan C; Ma Z; Xie J; Li W; Su L; Zhang G; Xu J; Wu Y; Zhang M; Liu W Signal Transduct Target Ther; 2023 Sep; 8(1):357. PubMed ID: 37726282 [TBL] [Abstract][Full Text] [Related]
42. [Pulmonary innate immune response in Sars-cov-2 infection]. Bottino E; Ponce AA Rev Fac Cien Med Univ Nac Cordoba; 2022 Mar; 79(1):33-42. PubMed ID: 35312259 [TBL] [Abstract][Full Text] [Related]
43. Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. Tangye SG; J Allergy Clin Immunol; 2023 Apr; 151(4):818-831. PubMed ID: 36522221 [TBL] [Abstract][Full Text] [Related]
44. Cellular Sensors and Viral Countermeasures: A Molecular Arms Race between Host and SARS-CoV-2. Sun H; Chan JF; Yuan S Viruses; 2023 Jan; 15(2):. PubMed ID: 36851564 [TBL] [Abstract][Full Text] [Related]
45. SARS-CoV-2: A Glance at the Innate Immune Response Elicited by Infection and Vaccination. Manfrini N; Notarbartolo S; Grifantini R; Pesce E Antibodies (Basel); 2024 Feb; 13(1):. PubMed ID: 38390874 [TBL] [Abstract][Full Text] [Related]
46. Why Do Some People Develop Serious COVID-19 Disease After Infection, While Others Only Exhibit Mild Symptoms? Ballow M; Haga CL J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1442-1448. PubMed ID: 33486141 [TBL] [Abstract][Full Text] [Related]
47. SARS-CoV-2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era? Chen J; Song J; Dai L; Post SR; Qin Z J Med Virol; 2022 Nov; 94(11):5103-5111. PubMed ID: 35819034 [TBL] [Abstract][Full Text] [Related]
48. The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update. Jasim SA; Mahdi RS; Bokov DO; Najm MAA; Sobirova GN; Bafoyeva ZO; Taifi A; Alkadir OKA; Mustafa YF; Mirzaei R; Karampoor S J Med Virol; 2022 Nov; 94(11):5128-5148. PubMed ID: 35835586 [TBL] [Abstract][Full Text] [Related]
49. Multiomics: unraveling the panoramic landscapes of SARS-CoV-2 infection. Wang X; Xu G; Liu X; Liu Y; Zhang S; Zhang Z Cell Mol Immunol; 2021 Oct; 18(10):2313-2324. PubMed ID: 34471261 [TBL] [Abstract][Full Text] [Related]
50. Role of Multiomics Data to Understand Host-Pathogen Interactions in COVID-19 Pathogenesis. Aggarwal S; Acharjee A; Mukherjee A; Baker MS; Srivastava S J Proteome Res; 2021 Feb; 20(2):1107-1132. PubMed ID: 33426872 [TBL] [Abstract][Full Text] [Related]
51. Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges. Hakim A; Hasan MM; Hasan M; Lokman SM; Azim KF; Raihan T; Chowdhury PA; Azad AK Front Microbiol; 2021; 12():637554. PubMed ID: 34512561 [TBL] [Abstract][Full Text] [Related]
52. The relationship between blood groups and risk of infection with SARS-CoV-2 or development of severe outcomes: A review. Shokri P; Golmohammadi S; Noori M; Nejadghaderi SA; Carson-Chahhoud K; Safiri S Rev Med Virol; 2022 Jan; 32(1):e2247. PubMed ID: 34997677 [TBL] [Abstract][Full Text] [Related]
53. Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host. Kheshtchin N; Bakhshi P; Arab S; Nourizadeh M Int Immunopharmacol; 2022 Apr; 105():108531. PubMed ID: 35074569 [TBL] [Abstract][Full Text] [Related]
54. COVID-19 in Patients with Cancer. Nowroozi A; Razi S; Sahu KK; Grizzi F; Arends J; Keshavarz-Fathi M; Rezaei N Adv Exp Med Biol; 2021; 1318():315-331. PubMed ID: 33973186 [TBL] [Abstract][Full Text] [Related]
55. Survival of SARS-CoV-2 in wastewater. Sherchan S; Thakali O; Ikner LA; Gerba CP Sci Total Environ; 2023 Jul; 882():163049. PubMed ID: 36990233 [TBL] [Abstract][Full Text] [Related]
56. The immune response to COVID-19: Does sex matter? Ho JQ; Sepand MR; Bigdelou B; Shekarian T; Esfandyarpour R; Chauhan P; Serpooshan V; Beura LK; Hutter G; Zanganeh S Immunology; 2022 Aug; 166(4):429-443. PubMed ID: 35470422 [TBL] [Abstract][Full Text] [Related]
58. Natural Immunity Boosters as Therapeutic Interventions in the Era of the COVID-19 Pandemic. Noureen S; Rehman K; Hamid Akash MS Endocr Metab Immune Disord Drug Targets; 2022; 22(8):842-851. PubMed ID: 35016600 [TBL] [Abstract][Full Text] [Related]
59. Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines. Akbar SMF; Al Mahtab M; Khan S Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992199 [TBL] [Abstract][Full Text] [Related]
60. The Landscape of Expressed Chimeric Transcripts in the Blood of Severe COVID-19 Infected Patients. Mukherjee SB; Detroja R; Mukherjee S; Frenkel-Morgenstern M Viruses; 2023 Feb; 15(2):. PubMed ID: 36851647 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]